HDAC9 and chondrosarcoma: In spite of the fact that the mechanisms underlying HDAC inhibitor sensitivity are currently unknown, the identification of novel treatment strategies for chondrosarcoma remains an important objective, especially for patients with unresectable or high-grade tumors.